Antidepressant medications and osteoporosis

Area of Science:

• Neuroendocrinology
• Pharmacology
• Bone Biology

Background:

• Serotonin receptors are present in bone cells, suggesting neuroendocrine regulation of bone metabolism.
• Depression itself is linked to increased fracture risk, potentially due to behavioral and biological factors.
• Antidepressants, particularly SSRIs and tricyclics, are widely used in depressed patients.

Purpose of the Study:

• To review current evidence on the impact of serotonin-acting antidepressants on bone mineral density (BMD) and osteoporosis.
• To identify future research directions concerning antidepressants and bone health.

Main Methods:

• Review of observational studies examining the relationship between depression, antidepressant use, and fracture risk.
• Analysis of evidence linking specific antidepressant classes (SSRIs, tricyclics) to BMD and fracture outcomes.
• Examination of dose-response relationships and temporal patterns of risk associated with antidepressant treatment.

Main Results:

• Current use of SSRIs and tricyclic agents is associated with a twofold increase in fracture risk compared to nonusers.
• A dose-response relationship exists for SSRIs, with varying effects across drug subclasses.
• Increased fracture risk peaks within months of treatment initiation and diminishes post-discontinuation.

Conclusions:

• SSRIs should be recognized as potential risk factors for osteoporotic fractures.
• The neuroendocrine system, via serotonin pathways, plays a significant role in bone health.
• Further research is needed to elucidate the complex interplay between depression, antidepressants, and bone metabolism.